The effect of Melatonin on Fatigue in Multiple sclerosis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017030120258N35

Enrollment

Registered

2017-04-27

Start date

2015-06-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: We prescribe 3 milligram Melatonin every night for 8 weeks. Intervention 2: In control group: We prescribe placebo for 8 weeks.

Treatment - Drugs

Intervention group: We prescribe 3 milligram Melatonin every night for 8 weeks.

In control group: We prescribe placebo for 8 weeks.

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: multiple sclerosis with Mc.donald score; 18 to 50 years; ?Expanded Disability Status Scale (EDSS) 0 to 5.5; multiple sclerosis with IFN-B. Exclusion criteria: pregnancy; ?patients with acute attack in 3 months ago; Lack of routine monitoring of ?patients. ?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fatigue. Timepoint: before treatment and 8 ?weeks after treatment. Method of measurement: standard fatigue questionnaire (FSS)?.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fardin Faraji

Arak University of Medical Sciences

faraji@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026